HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 167 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $50,302,000 | -7.8% | 5,091,303 | +12.7% | 0.01% | -18.2% |
Q3 2016 | $54,580,000 | +45.3% | 4,518,198 | +3.8% | 0.01% | +37.5% |
Q2 2016 | $37,560,000 | -7.8% | 4,352,218 | +1.2% | 0.01% | -11.1% |
Q1 2016 | $40,747,000 | -44.0% | 4,302,729 | +2.5% | 0.01% | -47.1% |
Q4 2015 | $72,762,000 | +22.1% | 4,198,609 | -5.4% | 0.02% | +13.3% |
Q3 2015 | $59,596,000 | -37.1% | 4,437,512 | +5.7% | 0.02% | -34.8% |
Q2 2015 | $94,816,000 | +57.9% | 4,199,129 | -0.1% | 0.02% | +64.3% |
Q1 2015 | $60,031,000 | +51.6% | 4,203,845 | +2.5% | 0.01% | +40.0% |
Q4 2014 | $39,592,000 | +15.8% | 4,102,773 | +9.2% | 0.01% | 0.0% |
Q3 2014 | $34,193,000 | -7.9% | 3,757,433 | +0.0% | 0.01% | 0.0% |
Q2 2014 | $37,106,000 | -26.2% | 3,755,627 | -5.1% | 0.01% | -33.3% |
Q1 2014 | $50,295,000 | -4.7% | 3,958,701 | +12.4% | 0.02% | -6.2% |
Q4 2013 | $52,778,000 | +35.6% | 3,520,891 | -0.1% | 0.02% | +23.1% |
Q3 2013 | $38,921,000 | +60.1% | 3,525,448 | +15.3% | 0.01% | +44.4% |
Q2 2013 | $24,314,000 | – | 3,058,315 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |
Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |